Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Deferred Taxes (2020 - 2021)

Insight Molecular Diagnostics (IMDX) has disclosed Deferred Taxes for 2 consecutive years, with $97000.0 as the latest value for Q4 2021.

  • Quarterly Deferred Taxes rose 161.01% to $97000.0 in Q4 2021 from the year-ago period, while the trailing twelve-month figure was -$9.3 million through Dec 2021, down 638.52% year-over-year, with the annual reading at -$9.3 million for FY2021, 638.52% down from the prior year.
  • Deferred Taxes hit $97000.0 in Q4 2021 for Insight Molecular Diagnostics, up from -$1.8 million in the prior quarter.
  • In the past five years, Deferred Taxes ranged from a high of $97000.0 in Q4 2021 to a low of -$7.6 million in Q1 2021.